| Expression pattern: |
UP |
| Associated gene: |
BCL2 |
| Associated microRNA: |
miR-618 |
| Biological function: |
CircCCDC66 promotes cisplatin resistance in gastric cancer, inhibits apoptosis, and supports progression of CDDP-resistant GC xenografts. |
| Molecular mechanism: |
CircCCDC66 functions as a miRNA sponge/competitive RNA for miR-618, relieving miR-618-mediated repression of BCL2 and inhibiting apoptosis to promote cisplatin resistance. |
| Biological pathway or process: |
apoptosis (inhibits); drug resistance (promotes); chemoresistance (promotes); ceRNA regulation (other); proliferation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; RT-qPCR; RNA-seq; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; TUNEL; Western Blot; In Vivo Animal Model; Cohort Study; Survival Analysis; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circCCDC66 expression is associated with CDDP resistance, malignancy, poor disease-free survival, and may predict CDDP resistance in gastric cancer patients treated with CDDP-based chemotherapy. |
| Description: |
CircCCDC66 is up-regulated in CDDP-resistant gastric cancer tissues and cell lines. It promotes cisplatin resistance by sponging miR-618 and relieving repression of BCL2, thereby inhibiting apoptosis. High circCCDC66 expression is associated with CDDP resistance and worse disease-free survival, suggesting biomarker and therapeutic-target potential. |
| Confidence score: |
0.8734 |